Investment Rating - The report indicates a positive outlook for the pharmaceutical and biotechnology sector, with a focus on the continued investment in domestic innovative drugs by multinational corporations (MNCs) [2]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.31%, outperforming the Wind All A index (0.41%) and the CSI 300 index (-0.43%). Key sub-sectors leading the gains included vaccines (3.38%), other biological products (3.33%), and chemical preparations (3.31%). Conversely, medical consumables (-1.98%), offline pharmacies (-1.84%), and medical devices (-1.45%) experienced declines [2][7]. - MNCs are increasingly investing in domestic innovative drugs, with significant collaborations and licensing agreements being established. Notable deals include the licensing of MWN105 by Lepu Medical to Sidera Bio, and Pfizer's registration of two global Phase III clinical studies for a dual antibody from 3SBio [2][12][13]. - Flu activity is on the rise, particularly in southern provinces, with reported ILI percentages indicating an increase compared to previous weeks and years [2][12]. Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector rose by 1.31%, outperforming the Wind All A index and the CSI 300 index. The leading sub-sectors were vaccines, other biological products, and chemical preparations, while medical consumables, offline pharmacies, and medical devices lagged [7][8][9]. Industry News and Key Company Announcements - Significant events include the initiation of the 2025 National Medical Insurance Directory negotiations, which will include a new category for innovative drugs under commercial health insurance [12]. - Lepu Medical's subsidiary licensed its innovative weight-loss drug MWN105 to Sidera Bio, with potential milestone payments reaching up to $1.01 billion [12][13]. - Pfizer registered two Phase III clinical studies for a dual antibody targeting advanced lung cancer and colorectal cancer [12][13]. - Roche entered a global exclusive collaboration with QX031N, a dual antibody developed by Qianxin Bio, with potential milestone payments of up to $995 million [12][13].

Core Viewpoint - He Yu Pharmaceutical announced the completion of the first patient dosing in a Phase II clinical study of its oral small molecule PD-L1 inhibitor ABSK043 in combination with the KRAS G12C inhibitor, Goresir, for the treatment of non-small cell lung cancer (NSCLC) with KRAS G12C mutations [1] Group 1: Clinical Study Details - The open-label Phase II clinical study aims to evaluate the safety, tolerability, and efficacy of ABSK043 combined with Goresir in patients with locally advanced or metastatic NSCLC carrying KRAS G12C mutations [1] - The study received approval from the National Medical Products Administration (NMPA) in China for a new drug clinical trial (IND) in August 2025 [1] - The successful dosing of the first patient marks a significant step in the clinical development of this promising combination therapy [1] Group 2: KRAS G12C Mutation Context - KRAS is the most common oncogenic driver gene in human cancers, with an occurrence rate of approximately 14% for KRAS G12C mutations in NSCLC patients [1] - The oral small molecule PD-L1 inhibitor ABSK043 has shown good safety and potential anti-tumor activity as a monotherapy in previous Phase I clinical studies involving advanced solid tumor patients, particularly in groups with high PD-L1 expression, EGFR mutations, and KRAS mutations [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Abbisko Cayman Limited 和譽開曼有限責任公司 （於開曼群島註冊成立的有限公司） （股份代號：2256） 自願性公告 和譽醫藥完成口服小分子PD-L1抑制劑ABSK043聯合 戈來雷塞治療NSCLC II期臨床首例患者給藥 和譽開曼有限責任公司（「本公司」，連同其附屬公司統稱「本集團」）謹此隨附新聞 稿，以告知本公司股東及潛在投資者，本公司之附屬公司上海和譽生物醫藥科技 有限公司（「和譽醫藥」）宣佈，其口服小分子PD-L1抑制劑ABSK043與上海艾力斯 醫藥科技股份有限公司（「艾力斯」）KRAS G12C抑制劑戈來雷塞聯合用於治療攜 帶KRAS G12C突變的非小細胞肺癌（「NSCLC」）的II期臨床研究已完成首例患者 給藥。 此為本公司刊發的自願性公告。本集團無法保證ABSK043最終將成功獲批上市。 本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 和譽開曼有 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The 2025 National Medical Insurance negotiation has commenced, with a focus on innovative drugs and a significant increase in the number and quality of applications for drugs outside the basic medical insurance directory [17][18]. - The report highlights a robust performance of the pharmaceutical sector, with the A-share pharmaceutical index showing a year-to-date increase of 21.1%, outperforming the CSI 300 index by 3.17% [4][9]. - The report emphasizes the long-term growth potential of China's innovative drug market, driven by a large patient pool, favorable policies, and a strong pipeline of innovative drugs [16]. Summary by Sections 1. Industry Performance - The A-share pharmaceutical index has increased by 1.31% this week and 21.1% year-to-date, with significant outperformance against the CSI 300 index [4][9]. - The Hang Seng Healthcare Index has shown a year-to-date increase of 73.53%, outperforming the Hang Seng Technology Index by 40.06% [4][9]. 2. R&D Progress and Company Dynamics - Pfizer has initiated two global Phase III clinical studies for PD-1/VEGF dual antibodies, targeting non-small cell lung cancer and colorectal cancer [4]. - The report notes that 310 generic names have passed the formal review for inclusion outside the basic medical insurance directory, marking a 24.5% increase from 2024 [18]. 3. Industry Insights and Regulatory Developments - The report ranks favored sub-industries as follows: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies [10][12]. - The report identifies key companies to watch, including Innovent Biologics, BeiGene, and Hengrui Medicine, among others, for their strong clinical competitiveness [12][18]. 4. Market Review - The report indicates that the pharmaceutical sector's adjustment has narrowed, with some sub-industries experiencing slight rebounds [4][9]. - The report provides a detailed overview of stock performance, highlighting significant gainers and losers in the A-share and H-share markets [4][9].

Core Viewpoint - The technology sector experienced significant declines, prompting a structural shift in market funds towards the innovative drug sector, which saw notable gains on the same day [1][3]. Group 1: Market Performance - The innovative drug sector rose by 3.91% amidst a downturn in the technology sector, successfully breaking through the 20-day moving average with increased trading volume, signaling positive market sentiment [3]. - The innovative drug sector had been in a downward trend since August but began to stabilize and form a bottom pattern in October [3]. Group 2: Multiple Sclerosis (MS) Market - The global market for MS drugs is projected to reach approximately $18.5 billion in 2024, with a significant portion of sales coming from third-generation products, particularly CD20 monoclonal antibodies [6]. - CD20 monoclonal antibodies are expected to account for over 60% of the MS drug sales in 2024, with the drug Ocrelizumab projected to generate sales of 7.64 billion yuan, reflecting a year-on-year growth of 7.4% [6]. Group 3: Chemical Pharmaceutical Industry - The global chemical pharmaceutical market grew from $1,038 billion in 2019 to $1,128 billion in 2023, with expectations to reach $1,156 billion in 2024 [10]. - In China, the chemical pharmaceutical market size was 883.9 billion yuan in 2022, with a year-on-year growth of 4.4%, projected to increase to 945 billion yuan by 2024 [10]. Group 4: Innovative Drug Sector Performance - In the first half of 2025, 21 A-share innovative drug companies reported revenues of 28.69 billion yuan, a year-on-year increase of 42%, while net losses narrowed significantly [11]. - The second quarter of 2025 saw these companies achieve revenues of 15.34 billion yuan, a 39% increase year-on-year, with net losses reduced by 97% [11][12]. Group 5: Future Outlook - Continued policy support for innovative drugs is expected to enhance performance, with an increase in product launches anticipated to drive revenue growth [15]. - The active business development (BD) transactions in the innovative drug sector in the first half of 2025 are expected to bolster the apparent performance of related companies [15].

Core Viewpoint - The article highlights a significant shift in market dynamics, with capital moving from the technology sector to the innovative drug sector, indicating a structural change in investment focus [2][5]. Market Performance - On October 31, major technology stocks experienced a sharp decline, while the innovative drug sector saw a notable increase, with a 3.91% rise, breaking through the 20-day moving average [6]. - The innovative drug sector has been in a downward trend since August but began to stabilize in October, suggesting a potential bottoming out [6]. Investment Opportunities - Investors are encouraged to identify potential investment opportunities within the innovative drug sector as it becomes the new focus for capital allocation [7]. - The market for Multiple Sclerosis (MS) drugs is projected to reach approximately $18.5 billion in 2024, indicating a substantial growth opportunity [9]. Industry Landscape - The global market for chemical pharmaceuticals has shown steady growth, with the market size increasing from $1,038 billion in 2019 to $1,128 billion in 2023, and expected to reach $1,156 billion in 2024 [17]. - In China, the chemical drug market size was approximately 883.9 billion yuan in 2022, with a projected increase to 945 billion yuan by 2024, reflecting strong growth potential [19]. Company Performance - In the first half of 2025, 21 A-share innovative drug companies reported a revenue of 28.69 billion yuan, a 42% year-on-year increase, while net losses narrowed significantly [20]. - The performance improvement is driven by the successful market penetration of key products and the approval of new drugs, contributing to revenue growth and reduced losses [20]. Future Outlook - Continued policy support for innovative drugs is expected to enhance performance and accelerate the product launch pace, leading to improved financial results for companies in this sector [24]. - The active business development (BD) transactions in the innovative drug sector during the first half of 2025 are anticipated to bolster the apparent performance of related companies [25]. - China's innovative drug industry is positioned to compete globally, with significant advantages in research efficiency and pipeline quality, supporting long-term growth trends [26].

Core Viewpoint - Ailis, a leading player in the domestic innovative drug sector, focuses on the research, production, and sales of innovative drugs, with its self-developed drug, Fumetinib, showcasing significant technological advantages [1] Group 1: Business Performance - For Q3 2025, Ailis reported revenue of 3.733 billion yuan, ranking 20th out of 110 in the industry, with the top company, East China Pharmaceutical, generating 32.664 billion yuan [2] - The net profit for the same period was 1.616 billion yuan, placing Ailis 7th in the industry, while the leading company, Heng Rui Medicine, reported a net profit of 5.76 billion yuan [2] Group 2: Financial Ratios - Ailis's debt-to-asset ratio stood at 10.48% in Q3 2025, slightly down from 10.49% year-on-year, significantly lower than the industry average of 35.26% [3] - The gross profit margin for Q3 2025 was 96.79%, an increase from 95.80% year-on-year, and well above the industry average of 57.17% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 46.82% to 19,100, while the average number of circulating A-shares held per shareholder decreased by 31.89% to 23,600 [5] Group 4: Executive Compensation - The chairman, Du Jinhao, received a salary of 4.9511 million yuan in 2024, an increase of 1.4204 million yuan from 2023 [4] Group 5: Analyst Ratings and Projections - Haitong International maintains an "outperform the market" rating for Ailis, projecting net profits of 1.929 billion yuan, 2.198 billion yuan, and 2.550 billion yuan for 2025-2027, with respective growth rates of 34.9%, 13.9%, and 16.0% [6] - Yongxing Securities holds a "buy" rating, forecasting revenues of approximately 5.02 billion yuan, 6.02 billion yuan, and 7.04 billion yuan for 2025-2027, with year-on-year growth rates of 41.0%, 19.9%, and 17.0% [7]

Core Viewpoint - The innovative drug sector has seen significant investment and stock price increases, with a notable rise in financing activities and institutional interest in high-performing stocks [1][7]. Market Performance - As of October 31, the market experienced fluctuations, with the ChiNext Index dropping over 1%. However, sectors such as AI applications, pharmaceuticals, and lithium batteries showed strength, while computing power stocks faced declines [2]. Innovative Drug Sector Developments - The innovative drug sector rebounded, with stocks like Sanofi's "20cm" hitting the daily limit, and other companies such as Zai Lab and Maiwei Biotech also seeing gains [3]. - The National Medical Insurance Negotiation for 2025 commenced on October 30, introducing a "Commercial Insurance Innovative Drug Directory" mechanism, which aims to include innovative drugs with high clinical value that are not yet part of the basic medical insurance directory [5][6]. Financial Performance and Institutional Interest - Year-to-date, the average stock price of innovative drug companies has increased by 49.01%, with nine stocks doubling in value. Notable performers include Shuyou Shen, Guangsheng Tang, and Rongchang Biotech, with increases of 330.77%, 236.36%, and 194.45%, respectively [7]. - In October, 15 innovative drug stocks received institutional research, with Huadong Medicine reporting a 62% year-on-year increase in sales and agency service revenue for innovative products [7]. - Ninezhou Pharmaceutical has also seen a positive outlook, with increased production capacity and a rise in clinical trial projects [7]. Earnings Reports - Among the innovative drug companies that released Q3 reports, WuXi AppTec reported the highest net profit, with a revenue of 32.857 billion yuan, up 18.61% year-on-year, and a net profit of 12.076 billion yuan, up 84.84% [8]. - Several companies, including Kexing Biotech and Chengdu Xian Dao, reported net profit increases exceeding 100% year-on-year [8]. - As of October 30, multiple high-performing innovative drug stocks have attracted increased financing, including WuXi AppTec, Lijuzhong Group, and Haoyuan Pharmaceutical [8].

Group 1 - The core viewpoint highlights the significant growth and performance of the Jiashi Science and Technology Medicine ETF, with a turnover rate of 10.94% and a transaction volume of 29.51 million yuan [3] - Over the past three months, the Jiashi Science and Technology Medicine ETF has seen an increase in scale by 45.74 million yuan, indicating substantial growth [3] - In terms of net value, as of October 30, 2025, the ETF has appreciated by 27.50% over the past year, with the highest monthly return since inception reaching 23.29% [3] Group 2 - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 50.63% of the total index, with leading companies including United Imaging Healthcare and BeiGene [4] - The performance of individual stocks shows varied growth, with notable increases such as 11.02% for Zai Lab and 10.79% for Rongchang Biopharmaceutical [6] Group 3 - The recent launch of the 2025 National Medical Insurance Negotiation introduces a dual-track adjustment model for basic medical insurance and commercial insurance, which is expected to alleviate the payment pressure for high-value innovative drugs [3] - The pharmaceutical sector has experienced a slight pullback, but there is a recovery in the demand for domestic innovative drug research and development, supported by a resurgence in capital market financing and an increase in overseas transactions of innovative drugs [3]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company reported a revenue of 3.733 billion yuan for Q3 2025, representing a year-on-year increase of 47.35%, with a net profit of 1.616 billion yuan, up 52.01% year-on-year [5] - The sales revenue of the drug Vomeletin is steadily increasing, enhancing patient accessibility and expanding the beneficiary population of lung cancer patients [8] - The company is expected to see revenue growth of 27.0%, 19.0%, and 13.7% for the years 2025, 2026, and 2027, respectively, with net profits of 1.593 billion yuan, 1.901 billion yuan, and 2.169 billion yuan for the same years [10] Financial Performance - For the first three quarters of 2025, the overall gross margin was 96.79%, an increase of 1.03 percentage points year-on-year, with an operating cash flow net amount of 1.730 billion yuan, up 39.94% year-on-year [7] - The company’s revenue for 2025 is projected to be 4.520 billion yuan, with a year-on-year growth of 27.0% [13] - The expected earnings per share (EPS) for 2025 is 3.54 yuan, with a price-to-earnings (P/E) ratio of 31.08 [13] Product Development and Market Strategy - The company has established a specialized team for rare target marketing, leveraging the clinical advantages of its products to enhance academic promotion and marketing strategies [9] - The drug Vomeletin has been recommended in the latest expert consensus for the treatment of advanced NSCLC with EGFR PACC mutations, further enhancing its clinical value [6][8] - The RET inhibitor product, Pujihua, is expected to enter the national medical insurance directory, improving drug accessibility for patients [10]